Online Services: Email Marketing - Internet Service Providers

Jets To Get Off To Running Start To Protect Rookie QB Mark Sanchez

As if this wasn’t known to many Jets fans, based on their two adolescent qaarterback’s Mark Sanchez and Kellen Clemens, their three-headed running back tandem of Thomas, Jones, Leon Washington and rookie Shonn Greene, the Jets will be a run-oriented offense when the conventional season rolls around. This certainly makes sense to me and also Rich Cimini of the New York Daily News.

In a course of 12 months, Brian Schottenheimer has gone from one quarterback extreme to the other. Brett Favre was a 38-year-old Scandinavian Edda, but stuck in his ways. Mark Sanchez is an impressionable rookie, a mere pup at 22.

Schottenheimer was forced to redo most of his playbook when Favre parachuted into the Jets’ sphere last summer, only three weeks before the start of the regular season. With Sanchez, the Jets’ offensive coordinator finds himself answering the most vital questions, such as correcting him the other day on the conference affiliation of a certain team.

The tougher situation for a coach? Schottenheimer smiled.

Absorbing response.

Schottenheimer, in his fourth season as the coordinator, looms as a key figure in the development of the Jets’ No.1 pick. He believes in a balanced offense, but with Favre the gunslinger in metropolis, the Jets’ pass-run ratio tilted toward the pass – 56% to 44%. Now, hoping to reduce the albatross on Sanchez, Schottenheimer probably will have to shift toward the run.

Rex Ryan has made no secret of his desire to follow the blueprint of the 2008 Ravens, who protected rookie quarterback Joe Flacco by tournament 592 times. Only one other team since 1987 has rushed more in a season – the 2004 Steelers, who ran 618 times. They, too, had a rookie quarterback, a lover by the name of Ben Roethlisberger.

If a team hits the 500 mark, it usually results in a playoff berth. Of the last 15teams to rush 500 times in a age, dating to 2006, 12 reached the postseason.

Prepare for the Meadowlands 500. Gentlemen, start your engines.

Read more...

Gilead to Buy CGI Pharmaceuticals for Up to $120 Million FOXBusiness

25.06.10

Gilead Sciences ( GILD ) scooped up privately-held CGI PharmaceuticalsMost of allfor up to $120 million on Friday as the company looks to bolster its chemical genetics platform.

After the arrangement closes, Gilead said CGI will continue operating in Branford, Conn., as wholly-owned subsidiary of Gilead. The companies see the handle closing in the third quarter.

Gilead said it plans to pay the majority of the price as an upfront payment, with the remainder based on clinical evolution progress. The acquisition will be financed through available cash on hand, Gilead said.

CGI is a increment-stage pharmaceutical company that focuses on small molecule chemistry and kinase biology.

“We are certain that Gilead’s knowledge and experience developing small molecule candidates for a range of clinical indicationsMost of allwill be instrumental in helping to progress our compounds toward clinical development for diseases where tremendous unmetBymedical need exists,” said Mark Velleca, the founder and senior vice president of CGI.

Source: